Schizophrenia/Psychosis

From ketamine response to differences between mTBI and concussion, here are highlights from the week in Psychiatric Times.

Will it hurt my baby? Researchers investigated associations between first trimester exposure to second-generation antipsychotics and major congenital malformations.

The FDA has accepted the NDA for aripiprazole 2-month, ready-to-use, long-acting injectable.

Long-acting injectable haloperidol decanoate may work as a treatment for Adderall-induced persistent psychosis.

A recent study demonstrates how large-scale, real-world data analyses can elucidate patterns of disease comorbidity.

Getting the “NAC” of treating negative symptoms: Researchers performed a randomized controlled trial of N-acetylcysteine in clozapine-resistant schizophrenia.

Alzheimer disease psychosis treatment pimavanserin receives Complete Response Letter from the FDA.

This novel schizophrenia treatment showed positive results in a phase 3 trial evaluating efficacy, safety, and tolerability.

The experts weighed in on a wide variety of psychiatric issues for the July 2022 issue of Psychiatric Times.

Exploring the association between methamphetamine use and the development of psychotic symptoms, such as paranoid delusions, ideas of reference, and auditory hallucinations.

It is time for gender-sensitive first-episode psychosis services.

Researchers performed a nationwide register-based study of primary antipsychotic nonadherence in schizophrenia.

The experts weighed in on a wide variety of psychiatric issues for the June 2022 issue of Psychiatric Times.

All mental health clinicians must now develop skills in cultural competence to avoid perpetuating disparities in health outcomes for BIPOC individuals with serious mental illnesses.

Over the past 6 months, Psychiatric Times has featured expert opinions on important psychiatric issues from psychosis to psychedelics.

Does the “early bird get the worm”? Researchers investigated long-term outcomes with an early-switch long-acting injectable antipsychotic in patients with schizophrenia using a population-based cohort.

Interim study results show 77% treatment response rate among participants.

Postpartum psychosis is experienced by 1 to 2 women every 1000 deliveries.

Sociocultural factors have been shown to impact both the presentation and course of schizophrenia/psychosis. Learn more here.

Researchers investigated population-level phenotypes occurring before and after diagnosis of schizophrenia using a large health insurance claims dataset.

In this Special Report, clearly delineate the clinical context of selective psychoses.

What are the benefits of early and comprehensive intervention for patients in their first episode of a serious mental illness?

"This pandemic represents an unprecedented time that requires a psychiatrist’s vigilance in identifying patients at risk for COVID-19–induced psychosis."

“In the general population, insomnia is associated with greater cognitive impairment, but its association (and potential sexual dimorphic effect) in schizophrenia is less clear.”

How do we find the right treatments for our patients with schizophrenia at every step of their journey?

A recent study examined hyperprolactinemia and antipsychotic therapy in patients with schizophrenia and Hashimoto's thyroiditis.

Evidence review focuses on bipolar disorder, psychosis, and major depression.

How is this new drug going to help in the treatment of agitation in patients with schizophrenia or bipolar disorder?

How can looking at the suffering of patients with schizophrenia through a psychodynamic lens help clinicians develop effective interventions and treatment plans?

The FDA has approved dexmedetomidine sublingual film for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.